ABSTRACT
Background Case management of symptomatic COVID-19 patients is a key health system intervention. The Kenyan government embarked to fill capacity gaps in essential and advanced critical care needed for the management of severe and critical COVID-19. However, given scarce resources, gaps in both essential and advanced critical care persist. This study assessed the cost-effectiveness of investments in essential and advanced critical care to inform the prioritization of investment decisions.
Methods We employed a decision tree model to assess the incremental cost-effectiveness of investment in essential care (EC) and investment in both essential and advanced critical care (EC+ACC) compared to current health care provision capacity (status quo) for COVID-19 patients in Kenya. We used a health system perspective, and an inpatient care episode time horizon. Cost data was obtained from primary empirical analysis while outcomes data was obtained from epidemiological model estimates. We used univariate and probabilistic sensitivity analysis (PSA) to assess the robustness of the results.
Results The status quo option is more costly and less effective compared to investment in essential care and is thus dominated by the later. The incremental cost effectiveness ratio (ICER) of Investment in essential and advanced critical care (EC+ACC) was US $1,378.21 per DALY averted and hence not a cost-effective strategy when compared to Kenya’s cost-effectiveness threshold (USD 908).
Conclusion When the criterion of cost-effectiveness is considered, and within the context of resource scarcity, Kenya will achieve better value for money if it prioritizes investments in essential care before investments in advanced critical care. This information on cost-effectiveness will however need to be considered as part of a multi-criteria decision-making framework that uses a range of criteria that reflect societal values of the Kenyan society.
What is already known?
The COVID-19 pandemic is responsible for substantial health effects in low- and middle-income countries
The case management of COVID-19 is one of the key control interventions deployed by country health systems.
Similar to other low- and middle-income countries, Kenya had substantial gaps in both essential and advanced critical care at the beginning of the pandemic.
What are the new findings?
Provision of essential care and advanced critical care for COVID-19 at the current health system capacity (status quo) was costly and the least effective strategy.
Investment in both essential care and advanced critical care for COVID-19 is not cost-effective in Kenya when compared to investment in essential care.
What do the new findings imply?
Prioritizing investments in filling capacity gaps in essential care before investing in filling capacity gaps in advanced critical care for COVID-19 is more cost-effective in Kenya
These findings are intended to inform the sequencing of investments in case management rather than the selection of either strategy, within a context of substantial resource constraint, and capacity gaps in both essential and advanced critical care or COVID-19
Kenya will need to consider these findings on cost-effectiveness within a multi-criteria decision-making framework that use a range of criteria that reflect societal values.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This manuscript is published with the permission of the director of KEMRI. The work is funded by the International Decision Support Initiative (IDSI). Additional funds from a Wellcome Trust core grant (#092654) supported this study. None of the authors or their institutions at any time received payment or services from a third party for any aspect of the submitted work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This is a modelling study that relied on data from published and publicly available papers to parametize the model
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data relevant to the study are included in the article and are available in publicly accessible published papers. The links to the studies that contain the data are provided in the supplementary file
